In patient samples of HNSCC, CIP2A was expressed in 82.7% and Oct4 in 36.5% of the studied tumor samples, respectively, and all Oct4 positive HNSCC tumours were also CIP2A positive. This evidence concerns the gene CIP2A and head and neck squamous cell carcinoma.